BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating) was the recipient of a large decrease in short interest during the month of December. As of December 30th, there was short interest totalling 1,200 shares, a decrease of 14.3% from the December 15th total of 1,400 shares. Based on an average trading volume of 44,700 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.
BioPlus Acquisition Stock Performance
NASDAQ:BIOS traded down $0.02 during mid-day trading on Friday, hitting $10.29. 3,580 shares of the company's stock traded hands, compared to its average volume of 72,005. BioPlus Acquisition has a 1 year low of $9.78 and a 1 year high of $10.31. The firm's 50 day simple moving average is $10.22 and its 200 day simple moving average is $10.10.
Get
BioPlus Acquisition alerts:
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Wealthspring Capital LLC purchased a new position in BioPlus Acquisition during the second quarter worth $394,000. Robinson Capital Management LLC purchased a new position in BioPlus Acquisition in the 2nd quarter valued at about $265,000. Polar Asset Management Partners Inc. raised its position in shares of BioPlus Acquisition by 31.0% in the third quarter. Polar Asset Management Partners Inc. now owns 1,056,666 shares of the company's stock valued at $10,619,000 after buying an additional 250,000 shares during the last quarter. First Trust Capital Management L.P. lifted its stake in shares of BioPlus Acquisition by 50.0% during the third quarter. First Trust Capital Management L.P. now owns 150,000 shares of the company's stock valued at $1,507,000 after buying an additional 50,000 shares during the period. Finally, Cantor Fitzgerald L. P. boosted its position in BioPlus Acquisition by 6.3% during the third quarter. Cantor Fitzgerald L. P. now owns 850,000 shares of the company's stock worth $8,542,000 after acquiring an additional 50,000 shares during the last quarter. 72.81% of the stock is owned by hedge funds and other institutional investors.
BioPlus Acquisition Company Profile
(Get Rating)
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
Recommended Stories
- Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
